T-cell profile at baseline. Activation/inhibitory receptor expression on T cells was assessed for patients with any prior anti-BCMA (A) or by the last prior anti-BCMA (all treated analysis set; cohort C) (B). Baseline CD4 and CD8 T-cell numbers trended lower in patients who received prior anti-BCMA CAR-T than those receiving prior BCMA-ADC therapy. However, expression of activation markers and inhibitory receptors was not upregulated on T cells from patients receiving a prior anti-BCMA CAR-T at any point during treatment or as the last line before teclistamab treatment compared with patients receiving prior BCMA-ADC therapy. The ANOVA tests assessed differences among groups of ADC, CAR-T, and ADC/CAR-T (A) and ADC, CAR-T, and non–anti-BCMA (B). ANOVA, analysis of variance; NR, Nonresponder; R, Responder.

T-cell profile at baseline. Activation/inhibitory receptor expression on T cells was assessed for patients with any prior anti-BCMA (A) or by the last prior anti-BCMA (all treated analysis set; cohort C) (B). Baseline CD4 and CD8 T-cell numbers trended lower in patients who received prior anti-BCMA CAR-T than those receiving prior BCMA-ADC therapy. However, expression of activation markers and inhibitory receptors was not upregulated on T cells from patients receiving a prior anti-BCMA CAR-T at any point during treatment or as the last line before teclistamab treatment compared with patients receiving prior BCMA-ADC therapy. The ANOVA tests assessed differences among groups of ADC, CAR-T, and ADC/CAR-T (A) and ADC, CAR-T, and non–anti-BCMA (B). ANOVA, analysis of variance; NR, Nonresponder; R, Responder.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal